Wednesday, June 21, 2006
Practice of Off-Label Marketing could expose Pharmas to False Claim Lawsuits
A report in Genetic Engineering News yesterday warned pharmaceutical companies that the enter a legal minefield when then they engage in off-label marketing of their products. The article recounts that in 2004, Pfizer had to pay penalties totalling $430 million for a subsidiary’s illicit promotional activities associated with off-label marketing, and warns that the prospect of enormous rewards could prompt employees of drug manufacturers to initiate whistleblower lawsuits against companies that violate the U.S. False Claims Act. Click the following link to read about the False Claims Act exposure in off-label marketing.
Posted by Quitam Help Admin on 06/21 at 02:01 PM
Page 1 of 1 pages
Printer Friendly Page